Lundbeck to Acquire Abide Therapeutics for $400M


  • Lundbeck acquires Abide, in all-stock transaction for $400M. Abide to receive $250M upfront and $150M development & commercialization milestones with its expected closure in Q2’19
  • The focus of the acquisition is to strengthen Lundbeck’s CNS portfolio with the addition of Abide’s candidate (ABX-1431) and a chemo-proteomic platform for developing serine hydrolase inhibitors (SHs) to treat multiple CNS disorders
  • Abide’s ABX-1431 is a selective inhibitor of serine hydrolase monoacylglycerol lipase (MGLL), increasing endocannabinoid signaling to restore homeostatic balance in CNS and is evaluated in P-IIa & P-I for Tourette syndrome & neuropathic pain respectively

Click here to read full press release/ article | Ref: Lundbeck | Image: Lundbeck